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Abstract
Background: The Satisfaction with Cancer Information Profile (SCIP) has previously been shown
to be a valid and reliable measure responsive to changes in patient satisfaction over time. It has
been suggested that the SCIP might be used to guide the tailored provision of treatment
information to patients with head and neck cancer but for this purpose the discrimination of the
SCIP, not its responsiveness, should be assessed. This paper assesses whether the SCIP is valid as
a discriminative measure suitable to guide tailored information.
Methods: The SCIP comprises two parts (SCIP-A and SCIP-B). The discrimination of both parts
was explored in a UK sample of 82 newly diagnosed patients with head and neck cancer. Principal
components analysis (PCA) was first used to explore the factor structure of the SCIP-A and SCIP-
B: discrimination analyses were then conducted at the level of full scale, subscale and item.
Results: Principal components analysis revealed a coherent three-factor solution for the SCIP-A
and a single factor for SCIP-B. Both parts of the SCIP proved to be discriminating at the full scale
level (SCIP-A Delta = 0.92; SCIP-B Delta = 0.90). The SCIP-A also proved to be discriminating at
the subscale level (Delta = 0.85 to 0.89). For the SCIP-A there was wide variation in the
discrimination of individual items, confirming its potential to tailor information at the item level. For
the SCIP-B, responses to most items indicated uniform satisfaction, suggesting that it would not be
useful for tailoring information at the item level.
Conclusion: The SCIP-A has been shown to be a valid discriminative measure and should prove
suitable for tailoring treatment information at the level of item, subscale and total scale score. The
SCIP-B, while a discriminating measure of total satisfaction, comprises too uniform a set of
indicators of patient satisfaction to make it useful for tailoring information at the item level. Overall,
the SCIP is valid as a measure of overall satisfaction with information about treatment and as a guide
to tailoring such information.
Background
In general, patients with cancer receive high-quality stand-
ard information [1] but often report a mismatch between
their individual informational requirements and that
actually provided [2-4]. It has been suggested that, while
a common baseline level of information should be pro-
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vided, patients would benefit from information provision
tailored to their individual needs [5]. This suggestion has
been supported by the National Cancer Alliance [6] which
recognises that generic information might not fulfil the
patients' requirements. Studies of patients with head and
neck cancer (HNC) for example, revealed a need for more
information about treatment options and the impact of
treatment than the operation itself [7,8].
The assessment of quality of information can take many
forms, from 'objective' evaluations of the accuracy of con-
tent, readability etc. [1] to more 'subjective' indices such
as the patient's preference for [9,10] or satisfaction
[11,12] with the information provided. While the former
may have more relevance for issues surrounding patient
knowledge and informed consent [13], the latter have
been found to have an impact on clinical outcomes: for
example, a recent study that found that lower levels of sat-
isfaction with information about treatment were predic-
tive of worse psychological outcomes in the longer term
[3]. A recent review of the literature [4], however, found
no assessment methods that took into account the
amount, content and timing of the information about
treatment for aspects such as recovery, side-effects and
long-term consequences. Though some measures of infor-
mational need in cancer exist [14-16], they fail to capture
the patient's perspective in terms of whether they have
received too much or too little information and the level
of information supplied. The recognition of the potential
for different information needs for different types of can-
cer led to the development of the Satisfaction with Cancer
Information Profile (SCIP) [17]. The SCIP has been vali-
dated as a reliable measure of satisfaction with informa-
tion about treatment, responsive to change [3,17] and it
has been suggested that this measure might guide a pro-
gramme of tailored information provision. For the SCIP
to be used for this purpose, however, requires that it be
able to discriminate between different levels of individual
satisfaction, and although validated in terms of being
responsive to change, previous studies have not examined
this aspect of the SCIP's validity. The SCIP might inform
the selective provision of information to patients in two
different ways. First, individual responses to the 14 items
contained in the first subscale of the SCIP may be used to
determine how information provision might be
improved, as suggested by others [10]. For this purpose
the discrimination of each item and the discrimination
and reliability of the whole 14-item scale are of interest: if
an individual item is insensitive to individual differences,
it will be of limited use in tailoring interventions. Second,
if there is an underlying structure to patient satisfaction
with information (as has been reported for the Satisfac-
tion with Information about Medicines Scale [18]), then
information might be tailored on the basis of the level of
satisfaction with each dimension. This might be required
if resources do not allow for the tailoring of information
to a precise (i.e. item-by-item) degree. For this purpose the
discrimination and reliability of the dimension sub-scales
would be of interest: if the sub-scales are unreliable or fail
to discriminate between patients then they will be of
doubtful value to inform focused interventions. This
study therefore sought to validate the SCIP as a discrimi-
native measure as a first step in establishing its usefulness
as a guide to tailored information provision.
Methods
Sample
The database for this analysis was derived from a previ-
ously published study [17]. A subset of the database (SCIP
item scores) was extracted for the full baseline sample of
82 patients newly diagnosed patients with HNC. These
had been recruited into a prospective study from four hos-
pitals in the southeast of England with a recruitment rate
of 76%: there were no significant differences in age, gen-
der or ethnicity between those recruited and those not
recruited. The mean age was 60 (SD = 13) with a range of
23 to 89 years. The sample was predominantly white
(92%) and male (66%), with most respondents married
or cohabiting (61%). Approximately one half of the sam-
ple was diagnosed with early-stage disease (stages I and II:
48%) and one half with advanced-stage disease (stages III
and IV: 46%). Stage at diagnosis was unobtainable for
three patients. The most common sites were tongue
(International Classification of Diseases [ICD]-10 C01
and C02) and laryngeal/glottis (ICD-10 C32). Initial
treatment plans were varied: 27% surgery only; 26% radi-
otherapy only; 31% surgery and radiotherapy; 11% radio-
therapy and chemotherapy and 5% surgery, radiotherapy,
and chemotherapy (5%). SCIP data were obtained after
diagnosis but before initial treatment.
Analysis
The SCIP comprises two sections (here referred to as SCIP-
A and SCIP-B for brevity). SCIP-A is a dichotomously
scored (satisfied/not satisfied) 14-item scale while SCIP-B
is a seven-item Likert-type scale (very dissatisfied to very
satisfied) (see appendices A and B respectively for item
listings). Because of the difference in scoring, different
analyses were required:
SCIP-A reliability
The reliability of the SCIP-A was analysed using the KR-20
formula: this provides an estimate of the degree of meas-
urement error in the scale score ranging from 1.0 (no
error) to 0.0 (total error).
SCIP-A scale discrimination
Full scale discrimination was examined using Ferguson's
Delta [19]. This provides an index of the degree of dis-
crimination provided by the scale ranging from 0.0 to 1.0.BMC Cancer 2008, 8:164 http://www.biomedcentral.com/1471-2407/8/164
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It may be interpreted directly as the proportion of discrim-
inations made in the sample, adjusted for the length of
the scale. A Delta of 0.8, for example, means that 80% of
all possible discriminations were made.
SCIP-A item analysis
The degree to which individual item responses predicted
the scale score (the item-total correlation) was examined
using the point-biserial correlation between each item
and the scale score. The point-biserial correlation is sim-
ply the Pearson correlation coefficient between a continu-
ous variable and a dichotomous variable and ranges from
0.0 (no association) to 1.0 (perfect prediction). Item dis-
crimination was computed using the formula given by
Allen & Yen [20]. This computes the difference in the
number of endorsements of an item between the top and
bottom thirds of the distribution, giving an index from
0.0 to 1.0. An index of 1.0 indicates perfect item discrimi-
nation, i.e. all of the most satisfied and none of least sat-
isfied respondents endorsed the item. In addition,
Ferguson's Delta was computed for each item, giving a sec-
ond index of item discrimination.
SCIP-B reliability
The reliability of the SCIP-B was analysed using Cron-
bach's Alpha. This ranges from 0.0 to 1.0, with the same
meaning and interpretation as the KR-20, above.
SCIP-B scale discrimination
Full scale discrimination was examined using Ferguson's
Delta adapted for Likert-type scales [21]; this Delta also
ranges from 0.0 to 1.0 and the meaning and interpretation
are the same as Delta, above.
SCIP-B item analysis
item-total correlations for each item were computed using
Pearson correlation coefficients. These range from 0.0 to
1.0 with the same meaning and interpretation as above.
Item discrimination using the Allen & Yen formula was
not possible as this formula is meaningful for dichoto-
mous items only. However, item discriminations were
computed using Delta, as above.
Sub-scale analysis
For both the SCIP-A and the SCIP-B the existence of mean-
ingful subscales was explored using principal components
analysis (PCA) with oblique rotation. This statistical
method identifies components ('factors') of the scale
scores. The exact number of factors was determined by
examination of a 'scree' plot, which plots each factor iden-
tified against the variance explained by the factors. A lev-
elling off of the curve suggests that further factors add little
to the variance explained. Once identified, the nature of
the components can be clarified by examining the associ-
ation between each item and the factors ('item loadings')
and the extent to which they explain the variation in scale
scores (the 'explained variance'). Subscales may then be
constructed from items having moderate to high loadings
on a given factor. Sub-scales can be interpreted as meas-
urements of different domains of satisfaction contributing
to the overall satisfaction score. Since respondents may be
more satisfied with one domain that another, they allow
for discrimination at a level between full scale (total) sat-
isfaction and the item-level satisfaction.
Results
Discrimination of SCIP-A
Table 1 shows the item analysis, reliability, and discrimi-
nation of SCIP-A. Since the items were dichotomous
Table 1: Item analysis, reliability and discrimination for SCIP-A
Item Item mean Item-total correlation Item discrimination Item Delta
1. Unwanted side-effects 0.78 0.63 0.61 0.62
2. Risks of side-effects 0.74 0.73 0.72 0.76
3. Risks of complications 0.59 0.66 0.89 0.92
4. Experience of side-effects 0.56 0.64 0.89 0.95
5. Interferes with medication 0.72 0.39 0.56 0.84
6. Feel after treatment 0.78 0.68 0.61 0.68
7. Ability to work 0.81 0.52 0.44 0.60
8. Financial support 0.61 0.41 0.61 0.98
9. Further treatment 0.78 0.59 0.61 0.74
10. Effect on appearance 0.81 0.59 0.50 0.69
11. Long term impact 0.76 0.50 0.50 0.80
12. Recovery time 0.67 0.53 0.61 0.89
13. Impact on QoL 0.61 0.63 0.78 0.95
14. Patient support 0.69 0.63 0.72 0.93
Scale KR-20 0.89
Scale Delta 0.92BMC Cancer 2008, 8:164 http://www.biomedcentral.com/1471-2407/8/164
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scores, the item means represent the proportion of
respondents satisfied with each item. It can be seen that
satisfaction ranged widely from item to item, with the
greatest satisfaction expressed for information about abil-
ity to work and effects of treatment on appearance (item
means = 0.81) and the least satisfaction expressed for
information about what to do if experiencing side-effects
(item mean = 0.56). Item-total correlations were also var-
iable, ranging from 0.39 to 0.73, suggesting that items
contributed to total satisfaction in varying degrees, as
expected. Similarly, item discriminations ranged from
0.44 to 0.89; this indicates that some items were much
more discriminating of high and low total satisfaction
than others. For example, risk of complications and what
to do if side effects were experienced had item discrimina-
tion scores of 0.89, indicating that satisfaction with these
items was a good indicator of high overall satisfaction.
Ability to work had an item discrimination score of 0.44,
suggesting that it was very undiscriminating of total satis-
faction. Item Delta coefficients assessed the ability of each
item to discriminate between individuals, ranging from
0.60 to 0.98. The least discriminating items were ability to
work and whether the treatment has any unwanted side
effects (Delta = 0.60 and 0.62), while the most discrimi-
nating were sources of financial support (Delta = 0.98),
what to do if experiencing side-effects and impact on qual-
ity of life (QoL) (both Delta = 0.95). Scale reliability and
scale discrimination were good (Alpha = 0.89; Delta =
0.92).
Factor structure of SCIP-A
Principal components analysis of the SCIP-A with oblique
rotation initially revealed 4 factors, with Eigen values
greater than 1, accounting for 61.7% of total variance.
Inspection of the fourth factor revealed that it comprised
two items, both of which loaded on one of the other three
factors: the scree plot also suggested a three factor solution
explaining 59.6% of total variance (Table 2). The first fac-
tor accounted for 40.9% of total variance and was inter-
preted as satisfaction with information about unwanted
effects (items 1,2,3,4,5; Alpha = 0.83; Delta = 0.87). The
second factor accounted for 10.6% of total variance and
was interpreted as satisfaction with information about
long-term effects (items 6,9,10,11,12,13; Alpha = 0.85;
Delta = 0.85). The third factor accounted for 8.1% of total
variance and was interpreted as satisfaction with informa-
tion about social/financial support (items 7,8,14; Alpha =
0.66; Delta = 0.89). The three subscales were significantly
correlated (unwanted effects and long-term effects r =
0.56, p < 0.001; unwanted effects and financial/social sup-
port r = 0.56, p < 0.001; long term effects and financial/
social support r = 0.52, p < 0.001).
Discrimination of SCIP-B
The reliability, discrimination and item analysis of the
SCIP-B are reported in Table 3. In general patients were
satisfied with the type of information received and the
timing, with mean item scores ranging from 3.7 to 4.2 (i.e.
'satisfied' on the five point integer scale). Item-correla-
tions were also high ranging from r = 0.52 to r = 0.74.
There was wide variability in individual items, however,
with standard deviations ranging from 0.5 to 1.0, suggest-
ing that some items might be more discriminating than
others. This was confirmed by the item Delta coefficients
ranging from low (usefulness and detail of information;
Delta = 0.71) to highly discriminating (written informa-
tion; Delta = 0.93). Scale reliability and discrimination
were satisfactory (Alpha = 0.87; Delta = 0.90).
Table 2: SCIP-A factor loadings following PCA
Item Item content Rotated on-factor loadings
Subscale 1: 'Unwanted effects'
1 Whether the treatment has any unwanted side-effects 0.77
2 What the risks of your experiencing side-effects are 0.75
3 What the risks of your experiencing complications are 0.75
4 What you should do if you experience unwanted side-effects 0.88
5 Whether your treatment interferes with other medicines you may be taking 0.21
Subscale 2: 'Long-term effects'
6 How you may expect to feel immediately after treatment 0.55
9 Whether you may need further treatment in the future 0.63
10 The effect of treatment on your appearance 0.38
11 The long-term impact of treatment on functioning (daily activities) 0.60
12 How long you expect recovery to take 0.89
13 How your treatment may impact on your quality of life over the next year 0.71
Subscale 3: 'Social/financial support'
7 The effects of treatment on your ability to work 0.59
8 Who to ask/where to go for possible financial support 0.85
14 Patient support groups for you and your partner 0.61BMC Cancer 2008, 8:164 http://www.biomedcentral.com/1471-2407/8/164
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Factor structure of SCIP-B
Principal components analysis with oblique rotation sug-
gested a single factor accounting for 61.0% of the total
variance (Table 4). Examination of the scree plot also sug-
gested a one-factor solution as the best fit. The SCIP-B was
therefore determined to be one-dimensional and no divi-
sion into subscales was necessary.
Discussion
For a measure to be useful in guiding tailored information
it must be able to discriminate between the differing
needs of individuals on a number of levels. Both sections
of the SCIP showed good discrimination at the level of
total satisfaction (SCIP-A Delta = 0.90; SCIP-B Delta =
0.93), demonstrating that the measures should prove use-
ful in determining which patients are in need of further
information in general. Additionally the SCIP-A further
subdivided into three coherent, correlated but distinct
areas of satisfaction (unwanted effects, long-term effects
and financial/social support). While the first two of these
subscales had acceptable reliability and all had adequate
discrimination, the financial support subscale was low in
reliability. Since this subscale comprised only three items,
this is perhaps not surprising: further development in
measuring this aspect of patient satisfaction is required.
However, it seems likely that the three subscales will also
prove useful as discriminating measures of patient satis-
faction within the broad domains so identified.
At the most patient-specific level of discrimination (dis-
crimination by item) some items proved more discrimi-
nating than others, particularly those of the SCIP-A. This
justifies the consideration of item-level responses, since
total satisfaction score was not consistently related to item
scores, and suggests that these items will be the most effec-
tive in identifying areas for additional or tailored provi-
sion of information.
As expected, those items uniformly high in satisfaction
across the sample were less useful in specifying how infor-
mation provision might be improved: this was especially
the case for the SCIP-B as the result of a 'ceiling effect' for
all of the items except the provision of written informa-
tion. Questionnaires measuring general or overall satisfac-
tion often suffer from this same lack of variability and it
may be that the response scale of SCIP-B should be further
adapted to increase the spread of scores [22].
We envisage that the SCIP will be useful in clinical set-
tings, research and audit. As a discriminating measure, it
should prove possible to tailor information provision at
the individual or group level, with the SCIP administered
immediately after the initial consultation, or indeed at
any stage in the course of treatment. For research, the SCIP
has now been validated for discriminative and evaluative
purposes and has been shown to be sensitive to individual
differences and change over time. For audit, the patient's
overall level of satisfaction with information provision
Table 3: Item analysis, reliability and discrimination for SCIP-B
Item Item mean Item SD Item-total correlation Item Delta
Usefulness of information to you 4.1 0.6 0.74 0.71
Usefulness to others 4.0 0.7 0.69 0.78
Written information 3.7 1.0 0.52 0.93
Verbal information 4.2 0.7 0.76 0.72
Timing of information 4.0 0.8 0.63 0.73
Detail of information 4.1 0.7 0.69 0.71
Understanding of information 4.2 0.5 0.67 0.54
Scale Alpha 0.87
Scale Delta 0.90
Table 4: Items included in SCIP-B with results from PCA
SCIP no. Item content Rotated on-factor loadings
15 The usefulness of the information to you 0.87
16 The usefulness of the information to your partner/family 0.85
17 The amount of written information supplied 0.82
18 The amount of verbal information supplied 0.79
19 The timing at which you received information 0.78
20 The detail of the information given to you 0.75
21 How understandable the information was to you 0.56BMC Cancer 2008, 8:164 http://www.biomedcentral.com/1471-2407/8/164
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may be assessed, and once again, changes in satisfaction
during the audit cycle noted.
The result of this study may, of course, reflect the particu-
lar concerns and response characteristics specific to
patients with head and neck cancer. It is possible that
some or all of these concerns extend to patients with other
forms of cancer, but we suggest that the SCIP be piloted
and further adapted (if required) before use in studies of
different populations.
Conclusion
The SCIP proved to be a reliable and discriminating meas-
ure of satisfaction suitable for guiding the tailoring of
information for patients with head and neck cancer. The
SCIP-A may be used to tailor the provision of information
based on total satisfaction score, subscale scores and item
scores. The SCIP-B is better suited to tailoring information
at the level of total satisfaction since it appears to be uni-
dimensional and comprises items with low individual dis-
crimination.
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Appendix: The SCIP questionnaire items and 
scoring
SCIP A
Do you feel as if you have received enough information
about:
1. Whether the treatment has any unwanted side effects
2. What the risks of your experiencing side effects are
3. What the risks of your experiencing complications are
4. What you should do if you experience unwanted side
effects 0 1 0 1
5. Whether your treatment interferes with other medicines
you may be taking
6. How you may expect to feel immediately after treat-
ment
7. The effects of treatment on your ability to work
8. Who to ask/where to go for possible financial support
9. Whether you may need further treatment in the future
10. The effect of treatment on your appearance
11. The long term impact of treatment on functioning
(daily activities)
12. How long you expect recovery to take
13. How your treatment may impact on your quality of
life over the next year
14. Patient support groups for you and your partner
Response choices: Too much/About right/Too little/None
wanted
Scoring: 0/1/0/1
Possible subscale score: 0–14
SCIP-B
Overall, how would you rate the following?
1. The usefulness of the information to you
2. The usefulness of the information to your partner/fam-
ily
3. The amount of written information supplied
4. The amount of verbal information supplied
5. The timing at which you received information
6. The detail of the information given to you
7. How understandable the information was to you
Response choices: Very satisfied/Satisfied/Neither/Dissat-
isfied/Very dissatisfied
Scoring: 5/4/3/2/1
Possible subscale score: 7–35
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